Based on these findings, changes in TRIP12 level is likely to play an oncogenic role in carcinogenesis and it has been proposed that TRIP12 could serve as a therapeutic target in specific scenarios i.e. when TRIP12 is dysregulated11 or specifically in acute myeloid leukemia where nucleophosmin is attenuated16. The gene discussed is NPM1; the disease is acute myeloid leukemia.